Adobe develops new technology in Basel
The US-based company Adobe is developing a technology in Basel that will make it possible to display content on screens more quickly. Basel is a central R&D location for the American software provider, says Christoph Kull, head of Central Europe at Adobe.
Computer chip (Img: stephen4/Pixabay)
Basel plays an important role for Adobe. “Basel is a central location for our research and development and is Europe’s largest training center for Adobe Experience Manager,” Christoph Kull, Vice President and Managing Director Central Europe at Adobe, is quoted in an article in the Sunday newspaper NZZ am Sonntag. “So many of today’s customer experiences also include architecture and innovation developed in Basel”.
The US software company is accelerating the development of its Adobe Experience Manager (AEM) from its offices in Basel, a program that allows users to centrally manage their data volumes and adapt them to their end devices. The global support center for critical AEM application cases also happens to be located in Basel, according to Florian Schaulin, manager of the Basel offices. The company is also currently working on a technology that will make it possible to display individual content on screens more quickly.
Adobe has been present in Basel since 2010, when it acquired Day Software, which was founded in 1993. Adobe’s employees come from prominent institutions including the Federal Institute of Technology in Zurich and the University of Basel. Adobe also supports the university financially and awards doctoral theses. In addition, Adobe offers four apprenticeships in Basel.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More